Literature DB >> 23637680

Lumbar posterolateral fusion with local bone graft plus bone extender compared with iliac crest bone graft: a systematic review.

Robert A McGuire1, Leslie E Pilcher, Joseph R Dettori.   

Abstract

STUDY
DESIGN: Systematic review. Study rationale and context:  Bone graft from the iliac crest has been the gold standard in posterolateral spinal fusion procedures, but is associated with chronic pain at the harvest site. Bone graft harvested locally from the spine and combined with extenders may decrease the morbidity associated with iliac graft harvest, but questions remain on the success of this technique to achieve bone union.
OBJECTIVES: Compare the fusion rate, functional outcomes, and safety of local bone graft plus bone extender compared with iliac crest bone graft in posterolateral spinal fusion procedures.
METHODS: A systematic review of the literature was undertaken for articles published through January 2011. Pubmed, Cochrane, National Guideline Clearinghouse Databases, and bibliographies of key articles were searched. Two independent reviewers studied the articles. Inclusion and exclusion criteria were set and each article was subject to a predefined quality-rating scheme.
RESULTS: We identified three articles meeting our inclusion criteria. Fusion rates were high across studies, with no significant differences between treatment groups in fusion, functional outcomes, or quality of life. There were two deep infections (5.3%) in one study among patients receiving local bone graft plus extender.
CONCLUSION: Local bone graft plus bone extender has similar fusion rates, functional outcomes, and patient quality-of-life scores as iliac crest bone graft in posterolateral spinal fusion procedures. Additional randomized trials with standardized methods of measuring fusion and functional outcomes are needed.

Entities:  

Year:  2011        PMID: 23637680      PMCID: PMC3621857          DOI: 10.1055/s-0030-1267103

Source DB:  PubMed          Journal:  Evid Based Spine Care J        ISSN: 1663-7976


Study Rationale and Context

Fusion of the spine is often required when treating instability and deformity. Classically, bone graft from the iliac crest has been the gold standard used to achieve this fusion. Studies reveal chronic pain with this graft harvest to be as high as 31%.5 Bone morphogenetic protein has been used to achieve fusion but also has associated complications and expense.6 This study looks at the success of achieving bone union using bone graft harvested locally from the spine and combined with extenders to decrease the morbidity associated with iliac crest graft harvest.

Objectives

To compare the fusion rate, functional outcomes, and safety of local bone graft plus bone extender compared with iliac crest bone graft (ICBG) in posterolateral spinal fusion procedures.

Materials and Methods

Systematic review. Sampling Search: PubMed, Cochrane collaboration database, and National Guideline Clearinghouse databases; bibliographies of key articles. Dates searched: through January 2011. (1) posterolateral lumbar fusion comparing local bone graft plus bone extender with ICBG and (2) comparative studies with concurrent controls. (1) Bone extender used without local bone graft; (2) prior lumbar surgery; and (3) case-series. fusion rate; functional status; quality of life (QoL); and complications. The proportion of patients achieving fusion was reported as the number of patients fused in each group divided by the total number of patients within the group. Functional and quality of life measures were recorded as mean score or mean percentage improvement compared with baseline. Overall strength of evidence was assessed using GRADE criteria. Details about methods can be found in the web appendix at www.aospine.org/ebsj.

Results

We identified three articles meeting inclusion criteria (Fig. 1). The indication for surgery was degenerative disc disease, spondylolisthesis, spinal stenosis, or deformity (Table 1). All three studies were randomized controlled trials, level of evidence I to II.1,2,3
Fig. 1

Results of literature search.

Table 1

Characteristics of included studies.*

AuthorStudy designPopulationCondition and treatmentInterventionControlFollow-up (%)Level of evidence
Alexander et al (2001)1Randomized trialN = 40

Mean age, y: 48 (range, 25–74)

67.5% male

Degenerative disc disease or spondylolisthesis (n = NR)Instrumented or noninstrumented posterolateral lumbar and lumbosacral spinal fusion with decompressionDecompression bone plus calcium sulfate pellets (OsteoSet®) on one side (n = 40)ICBG on other side (n = 40)1 y (80%)II
Dai and Jiang (2008)2Randomized trialN = 62beta-TCP + local autograft:

Mean age, y: NR (range, 48–72)

44% male

ICBG:

Mean age, y: NR (range, 51–73)

37% male

Degenerative lumbar spinal stenosisSingle-level instrumented posterolateral spinal fusion with decompressionbeta-TCP plus local autograft from decompression (n = 32)ICBG (n = 30)3 y (100%)II
Korovessis et al (2005)3Randomized trialN = 60ICBG:

Mean age, y: 61

% male NR

ICBG + HA + local bone + bone marrow:

Mean age, y: 64

% male: NR

HA + local bone + bone marrow:

Mean age, y: 58

% male: NR

Symptomatic degenerative lumbar spine stenosis with instabilityInstrumental posterolateral lumbar and lumbosacral fusion1. ICBG left side plus HA mixed with local bone and bone marrow of right (n = 20)2. HA mixed with local bone and bone marrow on both sides (n = 20)Bilateral ICBG (n = 20)Up to 4 y (95% at 3 y)II

NR indicates not reported; ICBG, iliac crest bone graft; TCP, tricalcium phosphate; and HA, hydroxyapatite.

Each patient received an intervention and control treatment and served as his own control.

Results of literature search. Mean age, y: 48 (range, 25–74) 67.5% male Mean age, y: NR (range, 48–72) 44% male Mean age, y: NR (range, 51–73) 37% male Mean age, y: 61 % male NR Mean age, y: 64 % male: NR Mean age, y: 58 % male: NR NR indicates not reported; ICBG, iliac crest bone graft; TCP, tricalcium phosphate; and HA, hydroxyapatite. Each patient received an intervention and control treatment and served as his own control. Further details on the class of evidence rating for these studies can be found in the supplemental material at www.aospine.org/ebsj. Fusion rates were high across studies, with fusion seen in 100% of patients treated with local bone plus extender and 100% of patients treated with ICBG. No significant differences in fusion rates were seen between treatment groups.2,3 One study comparing decompression bone plus calcium sulfate pellets (OsteoSet®) used on one side versus ICBG used on the other side found 88% of patients showed bone formation on the intervention side that was 75–100% of, equal to, or more than that on the control side at 12 months after fusion. Bone mass, as measured by comparing the posteroanterior x-ray with the lateral x-ray as reference, was 17.27 cm2 on the intervention side versus 17.25 cm2 on the control side.1 Two additional studies measuring fusion by agreement between independent observers based on Christensen' classification found reported fusion in all patients whether treated with local bone plus extender or ICBG.2,3 Fusion rates of bone extender plus local bone graft vs iliac bone crest graft. Functional status and QoL scores (Japanese Orthopedic Association, Oswestry Disability Index, SF-36) improved in all patient groups across studies, but no significant differences were found between treatment groups.2,3 Functional and QoL outcomes (A) mean score improvement at follow-up (F/U) vs baseline; (B) mean percentage improvement at follow-up vs baseline. Error bars represent 95% confidence intervals. Two studies reported complication rates; of these, one study found no complications in either treatment group and one found complications in both treatment groups; seeTable 2.2,3
Table 2

Complications.*

AuthorTreatment groupsComplications
Alexander et al (2001)1A. Decompression bone and calcium sulfate pellets on one sideB. ICBG on other sideNot reported
Dai and Jiang (2008)2 A. beta-TCP plus local autograft from decompressionB. ICBG plus decompressionA = noneB = none
Korovessis et al (2005)3 A. HA plus local bone and BMA on one side, ICBG on other sideB. HA plus local bone and BMA bilateralC. ICBG bilateralA = Deep infection (n = 1); superficial infection (n = 1)B = Deep infection (n = 1)C = Deep hematoma (n = 1); screw breakage (n = 1)

ICBG indicates iliac crest bone graft; TCP, tricalcium phosphate; HA, hydroxyapatite; and BMA, bone marrow aspirate.

Among patients treated with local bone plus extender, two had deep infections (5.3%), and one had a superficial infection.3 Among patients treated with ICBG, one had a deep hematoma and a second had a screw breakage.3

Complications

Dai and Jiang:2 intervention indicates β-tricalcium phosphate plus local autograft; and control, iliac crest bone graft. Korovessis et al:3 intervention A indicates hydroxyapatite with bone marrow aspirate plus local bone on one side, iliac crest bone graft on the other; intervention B, hydroxyapatite with bone marrow aspirate plus local bone on both sides; and control, iliac crest bone graft on both sides. Dai and Jiang:2 intervention indicates β-tricalcium phosphate plus local autograft; and control, iliac crest bone graft. Korovessis et al:3 intervention A indicates hydroxyapatite with bone marrow aspirate plus local bone on one side, iliac crest bone graft on the other; intervention B, hydroxyapatite with bone marrow aspirate plus local bone on both sides; and control, iliac crest bone graft on both sides. ICBG indicates iliac crest bone graft; TCP, tricalcium phosphate; HA, hydroxyapatite; and BMA, bone marrow aspirate.

Clinical Guidelines

The American Association of Neurological Surgeons/Congress of Neurological Surgeons has released one guideline related to use of bone graft extenders and substitutes.4 This guideline does not offer recommendations related to the use of local bone plus extender.

Illustrative Case

A 45-year-old man was admitted for decompression and fusion for lateral recess stenosis and instability. The bone harvested locally from the spinal decompression was combined with demineralized bone matrix for a posterolateral fusion. The results are seen in the AP and lateral x-ray 6 years postoperatively. Note the mature bone in the posterolateral gutter bilaterally at the L4/5 level (Fig. 4,Fig. 5).
Fig. 4

AP x-ray reveals excellent bone growth and stable intertransverse fusion at the L4/5 level.

Fig. 5

Lateral x-ray reveals excellent bone mass in the posterolateral space between L4/5.

AP x-ray reveals excellent bone growth and stable intertransverse fusion at the L4/5 level. Lateral x-ray reveals excellent bone mass in the posterolateral space between L4/5. In the three comparative studies that evaluated local bone graft plus bone extender for posterolateral lumbar fusion, fusion rates, functional outcomes, and QoL outcomes were similar in patients treated with the extender or with ICBG. There were two deep infections (5.3%) in one study among patients receiving local bone graft plus extender. This systematic review is limited by the following: Significant heterogeneity among studies with respect to variation in the type of test materials used, procedural details, and methods of comparing test material with ICBG. Discordant functional or lack of functional and QoL outcomes. Varying definitions of fusion and disparate ways of assessing. The use of locally harvested bone from the spine combined with extenders or extenders plus bone marrow aspirate has been shown to be equivalent to that of ICBG but without associated morbidity.
Fusion
OutcomesStrength of evidence*Conclusions/Comments
1. Rate of fusionFusion rates were high and similar across treatment groups
Functional status and QoL
1. Functional scoresFunctional status scores improved after fusion and did not differ significantly between treatment groups
2. QoL scoresQoL scores improved after fusion and did not differ significantly between treatment groups
Complications
1. ComplicationsComplications were rare, but one study reported a 5.3% rate of deep infection in patients treated with local bone plus extender
  6 in total

1.  Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 16: bone graft extenders and substitutes.

Authors:  Daniel K Resnick; Tanvir F Choudhri; Andrew T Dailey; Michael W Groff; Larry Khoo; Paul G Matz; Praveen Mummaneni; William C Watters; Jeffrey Wang; Beverly C Walters; Mark N Hadley
Journal:  J Neurosurg Spine       Date:  2005-06

2.  Commercially funded and United States-based research is more likely to be published; good-quality studies with negative outcomes are not.

Authors:  Joseph R Lynch; Mary R A Cunningham; Winston J Warme; Douglas C Schaad; Fredric M Wolf; Seth S Leopold
Journal:  J Bone Joint Surg Am       Date:  2007-05       Impact factor: 5.284

3.  Correlative radiological, self-assessment and clinical analysis of evolution in instrumented dorsal and lateral fusion for degenerative lumbar spine disease. Autograft versus coralline hydroxyapatite.

Authors:  Panagiotis Korovessis; Georgios Koureas; Spyridon Zacharatos; Zisis Papazisis; Elias Lambiris
Journal:  Eur Spine J       Date:  2005-03-24       Impact factor: 3.134

4.  Efficacy of calcium sulfate plus decompression bone in lumbar and lumbosacral spinal fusion: preliminary results in 40 patients.

Authors:  D I Alexander; N A Manson; M J Mitchell
Journal:  Can J Surg       Date:  2001-08       Impact factor: 2.089

5.  Iliac crest bone graft donor site pain after anterior lumbar interbody fusion: a prospective patient satisfaction outcome assessment.

Authors:  Rick C Sasso; Jean Charles LeHuec; Christopher Shaffrey
Journal:  J Spinal Disord Tech       Date:  2005-02

6.  Single-level instrumented posterolateral fusion of lumbar spine with beta-tricalcium phosphate versus autograft: a prospective, randomized study with 3-year follow-up.

Authors:  Li-Yang Dai; Lei-Sheng Jiang
Journal:  Spine (Phila Pa 1976)       Date:  2008-05-20       Impact factor: 3.468

  6 in total
  1 in total

1.  A Review and Analysis of the YODA Trials: What Can We Glean Clinically?

Authors:  Michael E Le; Mark F Kurd
Journal:  Curr Rev Musculoskelet Med       Date:  2014-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.